Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Welch, W. J.
Right arrow Articles by Diamond, M. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welch, W. J.
Right arrow Articles by Diamond, M. I.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2001, Vol. 10, No. 26 3063-3074
© 2001 Oxford University Press

Glucocorticoid modulation of androgen receptor nuclear aggregation and cellular toxicity is associated with distinct forms of soluble expanded polyglutamine protein

William J. Welch1 and Marc I. Diamond+

Departments of Neurology, and Cellular and Molecular Pharmacology and 1Departments of Surgery, Medicine and Physiology, University of California, San Francisco, CA 94143-0450, USA

Spinobulbar muscular atrophy is a progressive motor neuron disease caused by abnormal polyglutamine tract expansion in the androgen receptor (AR) gene, and is part of a family of central nervous system (CNS) neurodegenerative diseases, including Huntington’s disease (HD). Each pathologic protein is widely expressed, but the cause of neuronal degeneration within the CNS remains unknown. Many reports now link abnormal polyglutamine protein aggregation to pathogenesis. A previous study reported that activation of the wild-type glucocorticoid receptor (wtGR) suppressed the aggregation of expanded polyglutamine proteins derived from AR and huntingtin, whereas a mutant receptor containing an internal deletion, GR{Delta}108–317, increased polyglutamine protein aggregation, in this case primarily within the nucleus. In this study, we use these two forms of GR to study expanded polyglutamine AR protein in different cell contexts. Using cell biology and biochemical approaches, we find that wtGR promotes soluble forms of the protein and prevents nuclear aggregation in NIH3T3 cells and cultured neurons. In contrast, GR{Delta}108–317 decreases polyglutamine protein solubility, and causes formation of nuclear aggregates in non-neuronal cells. Nuclear aggregates recruit hsp72 more rapidly than cytoplasmic aggregates, and are associated with decreased cell viability. Limited proteolysis and chemical cross-linking suggest unique soluble forms of the expanded AR protein underlie these distinct biological activities. These observations provide an experimental framework to understand why expanded polyglutamine proteins may be toxic only to certain populations of cells, and suggest that unique protein associations or conformations of expanded polyglutamine proteins may determine subsequent cellular effects such as nuclear localization and cellular toxicity.

+ To whom correspondence should be addressed. Tel: +1 415 476 2251; Fax: +1 415 502 8644; Email: marcd@itsa.ucsf.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
J. Shao, W. J. Welch, N. A. DiProspero, and M. I. Diamond
Phosphorylation of Profilin by ROCK1 Regulates Polyglutamine Aggregation
Mol. Cell. Biol., September 1, 2008; 28(17): 5196 - 5208.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. Shao and M. I. Diamond
Polyglutamine diseases: emerging concepts in pathogenesis and therapy
Hum. Mol. Genet., October 15, 2007; 16(R2): R115 - R123.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
U. A. Desai, J. Pallos, A. A. K. Ma, B. R. Stockwell, L. M. Thompson, J. L. Marsh, and M. I. Diamond
Biologically active molecules that reduce polyglutamine aggregation and toxicity
Hum. Mol. Genet., July 1, 2006; 15(13): 2114 - 2124.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. A. LaFevre-Bernt and L. M. Ellerby
Kennedy's Disease: PHOSPHORYLATION OF THE POLYGLUTAMINE-EXPANDED FORM OF ANDROGEN RECEPTOR REGULATES ITS CLEVAGE BY CASPASE-3 AND ENHANCES CELL DEATH
J. Biol. Chem., September 12, 2003; 278(37): 34918 - 34924.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
K.J. Cowan, M.I. Diamond, and W.J. Welch
Polyglutamine protein aggregation and toxicity are linked to the cellular stress response
Hum. Mol. Genet., June 15, 2003; 12(12): 1377 - 1391.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
T. Okuda, H. Hattori, S. Takeuchi, J. Shimizu, H. Ueda, J. J. Palvimo, I. Kanazawa, H. Kawano, M. Nakagawa, and H. Okazawa
PQBP-1 transgenic mice show a late-onset motor neuron disease-like phenotype
Hum. Mol. Genet., April 1, 2003; 12(7): 711 - 725.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. L. Walcott and D. E. Merry
Ligand Promotes Intranuclear Inclusions in a Novel Cell Model of Spinal and Bulbar Muscular Atrophy
J. Biol. Chem., December 20, 2002; 277(52): 50855 - 50859.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Dejager, H. Bry-Gauillard, E. Bruckert, B. Eymard, F. Salachas, E. LeGuern, S. Tardieu, R. Chadarevian, P. Giral, and G. Turpin
A Comprehensive Endocrine Description of Kennedy's Disease Revealing Androgen Insensitivity Linked to CAG Repeat Length
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3893 - 3901.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.